Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.
ADVANCED SEARCH
Log in
Top
Strahlentherapie und Onkologie
Published in: Strahlentherapie und Onkologie 9/2015

01-09-2015 | Literatur kommentiert

FDG-PET bei der Involved-Node-Bestrahlung von Hodgkin-Lymphomen zur Zielvolumendefinition hilfreich

Authors: Dr. Jan Kriz, Prof. Dr. med. Hans Theodor Eich

Published in: Strahlentherapie und Onkologie | Issue 9/2015

Login to get access

Auszug

Die Standardbehandlung für Patienten in frühen günstigen und frühen ungünstigen Stadien eines Hodgkin-Lymphoms (HL) besteht aus einer Polychemotherapie, gefolgt von einer konsolidierenden Involved-Field-Radiotherapie (IF-RT). Da nach einer IF-RT unter Umständen Spätfolgen auftreten können, wird aktuell im Rahmen der internationalen Studiengruppen der Stellenwert einer Involved-Node-Radiotherapie (IN-RT) geprüft. Die vorliegende Auswertung beleuchtet den Stellenwert des PET-CT bei der Konturierung des Planungszielvolumens (PTV) der IN-RT. …
Literature
1.
Engert A, Haverkamp H, Kobe C, Markova J, Renner C, Ho A et al (2012) Reduced intensity of chemotherapy and PET-giuded radiotherapy in patients with advanced stage Hodgkin lymphoma: an open-label, randomised phase 3 trial. Lancet 379:1791–1799CrossRefPubMed
2.
Raemaekers JM, André MP, Federico M et al (2014) Omitting radiotherapy in early positron emission tomography-negative stage I/II Hodgkin lymphoma is associated with an increased risk of early relapse: clinical results of the preplanned interim analysis of the randomized EORTC/LYSA/FIL H10 trial. J Clin Oncol 32:1188–1194CrossRefPubMed
3.
Radford J, Illidge T, Counsell N et al (2015) Results of a trial of PET-Directed Therapy for Early-Stage Hodgkin’s Lymphoma. New Engl J Med 372:1598–1607
4.
Engert A, Plutschow A, Eich HT, Lohri A, Dorken B, Borchmann P et al (2010) Reduced treatment intensity in patients with early-stage Hodgkin’s lymphoma. N Engl J Med 363:640–652CrossRefPubMed
5.
Specht L, Yahalom J, Illidge T et al (2013) Modern radiation therapy for Hodgkin lymphoma: field and dose guidelines from the International Lymphoma Radiation Oncology Group (ILROG). Int J Rad Oncol Biol Phys 89(4):854–862
6.
Eich HT, Engenhart-Cabillic R, Hansemann K et al (2008) Quality control of involved field radiotherapy in patients with early-favorable (HD10) and early-unfavorable (HD11) Hodgkin’s lymphoma: an analysis of the German Hodgkin Study Group. Int J Radiat Oncol Biol Phys 71:1419–1424CrossRefPubMed
7.
Kriz J, Reinartz G, Dietlein M et al (2015) Relapse analysis of irradiated patients within the HD15 trial of the German Hodgkin Study Group. Int J Radiat Oncol Biol Phys 92(1):46–53. doi: 10.1016/j.ijrobp.2015.01.048
Metadata
Title
FDG-PET bei der Involved-Node-Bestrahlung von Hodgkin-Lymphomen zur Zielvolumendefinition hilfreich
Authors
Dr. Jan Kriz
Prof. Dr. med. Hans Theodor Eich
Publication date
01-09-2015
Publisher
Springer Berlin Heidelberg
Published in
Strahlentherapie und Onkologie / Issue 9/2015
Print ISSN: 0179-7158
Electronic ISSN: 1439-099X
DOI
https://doi.org/10.1007/s00066-015-0869-4

Other articles of this Issue 9/2015

Strahlentherapie und Onkologie 9/2015 Go to the issue

Literatur kommentiert

Orale Bisphosphonate senken möglicherweise die Inzidenz von postmenopausalen Korpuskarzinomen

Literatur kommentiert

Akzelerierte Teilbrustbestrahlung mit interstitieller Brachytherapie

Original Article

The importance of surrounding tissues and window settings for contouring of moving targets

Original Article

DEGRO practical guidelines for radiotherapy of non-malignant disorders

Original Article

Deep inspiration breath-hold (DIBH) radiotherapy in left-sided breast cancer

Original Article

Breath-hold technique in conventional APPA or intensity-modulated radiotherapy for Hodgkin’s lymphoma